The 'aspirin' of the new millennium: Cyclooxygenase-2 inhibitors

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit prostaglandin synthesis via the cyclooxygenase (COX) enzyme, the key to both therapeutic benefits and toxicity. COX enzyme exists in 2 isoforms, COX-1 and COX-2. COX-1 enzyme is thought to mediate 'housekeeping' or homeostatic functions, and COX-2 is considered an inducible enzyme in response to injury or inflammation. COX-2 inhibitors are the 'next-generation' NSAIDs that may selectively block the COX-2 isoenzyme without affecting COX-1 function. This may result in control of pain and inflammation with a lower rate of adverse effects compared with older nonselective NSAIDs. Rapidly evolving evidence suggests that COX-2 enzyme has a diverse physiologic and pathologic role. This article addresses the role of COX-2 enzyme in health and disease as well as the potential therapeutic value and safety issues related to COX-2 inhibition.

Original languageEnglish (US)
Pages (from-to)1027-1038
Number of pages12
JournalMayo Clinic Proceedings
Volume75
Issue number10
StatePublished - 2000

Fingerprint

Cyclooxygenase 2 Inhibitors
Cyclooxygenase 2
Aspirin
Cyclooxygenase 1
Enzymes
Anti-Inflammatory Agents
Prostaglandin-Endoperoxide Synthases
Pharmaceutical Preparations
Inflammation
Housekeeping
Isoenzymes
Prostaglandins
Protein Isoforms
Safety
Pain
Health
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The 'aspirin' of the new millennium : Cyclooxygenase-2 inhibitors. / Buttar, Navtej Singh; Wang, Kenneth Ke Ning.

In: Mayo Clinic Proceedings, Vol. 75, No. 10, 2000, p. 1027-1038.

Research output: Contribution to journalArticle

@article{6c7edb8b6682401c84cb48b9cf5cb11f,
title = "The 'aspirin' of the new millennium: Cyclooxygenase-2 inhibitors",
abstract = "Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit prostaglandin synthesis via the cyclooxygenase (COX) enzyme, the key to both therapeutic benefits and toxicity. COX enzyme exists in 2 isoforms, COX-1 and COX-2. COX-1 enzyme is thought to mediate 'housekeeping' or homeostatic functions, and COX-2 is considered an inducible enzyme in response to injury or inflammation. COX-2 inhibitors are the 'next-generation' NSAIDs that may selectively block the COX-2 isoenzyme without affecting COX-1 function. This may result in control of pain and inflammation with a lower rate of adverse effects compared with older nonselective NSAIDs. Rapidly evolving evidence suggests that COX-2 enzyme has a diverse physiologic and pathologic role. This article addresses the role of COX-2 enzyme in health and disease as well as the potential therapeutic value and safety issues related to COX-2 inhibition.",
author = "Buttar, {Navtej Singh} and Wang, {Kenneth Ke Ning}",
year = "2000",
language = "English (US)",
volume = "75",
pages = "1027--1038",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - The 'aspirin' of the new millennium

T2 - Cyclooxygenase-2 inhibitors

AU - Buttar, Navtej Singh

AU - Wang, Kenneth Ke Ning

PY - 2000

Y1 - 2000

N2 - Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit prostaglandin synthesis via the cyclooxygenase (COX) enzyme, the key to both therapeutic benefits and toxicity. COX enzyme exists in 2 isoforms, COX-1 and COX-2. COX-1 enzyme is thought to mediate 'housekeeping' or homeostatic functions, and COX-2 is considered an inducible enzyme in response to injury or inflammation. COX-2 inhibitors are the 'next-generation' NSAIDs that may selectively block the COX-2 isoenzyme without affecting COX-1 function. This may result in control of pain and inflammation with a lower rate of adverse effects compared with older nonselective NSAIDs. Rapidly evolving evidence suggests that COX-2 enzyme has a diverse physiologic and pathologic role. This article addresses the role of COX-2 enzyme in health and disease as well as the potential therapeutic value and safety issues related to COX-2 inhibition.

AB - Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit prostaglandin synthesis via the cyclooxygenase (COX) enzyme, the key to both therapeutic benefits and toxicity. COX enzyme exists in 2 isoforms, COX-1 and COX-2. COX-1 enzyme is thought to mediate 'housekeeping' or homeostatic functions, and COX-2 is considered an inducible enzyme in response to injury or inflammation. COX-2 inhibitors are the 'next-generation' NSAIDs that may selectively block the COX-2 isoenzyme without affecting COX-1 function. This may result in control of pain and inflammation with a lower rate of adverse effects compared with older nonselective NSAIDs. Rapidly evolving evidence suggests that COX-2 enzyme has a diverse physiologic and pathologic role. This article addresses the role of COX-2 enzyme in health and disease as well as the potential therapeutic value and safety issues related to COX-2 inhibition.

UR - http://www.scopus.com/inward/record.url?scp=0033805055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033805055&partnerID=8YFLogxK

M3 - Article

C2 - 11040851

AN - SCOPUS:0033805055

VL - 75

SP - 1027

EP - 1038

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -